NCT06934200 Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels Status RECRUITING Phase PHASE2
NCT06042478 Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension. Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT00382148 A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g Status COMPLETED Phase PHASE2